{"id":1018794,"date":"2026-11-09T10:05:35","date_gmt":"2026-11-09T15:05:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/"},"modified":"2026-11-09T10:05:35","modified_gmt":"2026-11-09T15:05:35","slug":"pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","title":{"rendered":"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PLN-101095 at the 41st<\/sup> Annual Meeting of the Society for Immunotherapy of Cancer (SITC).<\/p>\n

\n Poster Presentations<\/strong>\n <\/p>\n

\n Title:<\/strong> Selective targeting of integrins \u03b1v\u03b28 and \u03b1v\u03b21 improves anti-tumor responses mediated by immune checkpoint inhibition<\/p>\n

Nika Rajabian, Ph.D., Postdoctoral Fellow from the National Cancer Institute, presented data demonstrating that blocking of integrins \u03b1v\u03b28 and \u03b1v\u03b21 in combination with anti-PD-1 reduced TGF-\u03b2 signaling leading to modulation of fibroblastic cell populations in the tumor microenvironment and increased infiltration and activation of cytotoxic CD8+<\/sup> T cells. This resulted in improved anti-tumor activity and survival. Researchers concluded that these data provided rationale for an ongoing, first-in-human phase I clinical trial (NCT06270706<\/a>) of PLN-101095 in combination with pembrolizumab in solid cancers.<\/p>\n

The above reflects work done under a collaboration agreement between the National Cancer Institute and Pliant Therapeutics.<\/p>\n

\n Title:<\/strong> Plasma biomarkers of immune activation predict sensitization to immune checkpoint inhibition (ICI) in patients with advanced solid tumors receiving dual \u03b1v\u03b28\/\u03b1v\u03b21 integrin inhibitor PLN-101095<\/p>\n

Martin L. Decaris, Ph.D., Vice President of Translational Sciences at Pliant Therapeutics presented new biomarker data from the Phase 1 trial of PLN-101095 showing that early induction of immune activation biomarkers during PLN-101095 monotherapy was associated with subsequent clinical response following pembrolizumab initiation. These findings support the hypothesis that TGF-\u03b2 pathway inhibition promotes immune activation, T-cell recruitment into the tumor microenvironment, and enhanced cytotoxic effector function.<\/p>\n

This poster is available in the Publications section of Pliant\u2019s website www.PliantRx.com<\/a>.<\/p>\n

\n FORTIFY – PLN-101095 Phase 1b Indication Expansion Trial<\/strong>\n <\/p>\n

PLN-101095 is currently being evaluated in a Phase 1a\/1b open-label, dose-escalation and indication expansion trial (NCT06270706<\/a>) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with\u00a0pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. The Phase 1b portion of FORTIFY is an indication expansion trial that is currently enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.<\/p>\n

\n About Pliant Therapeutics, Inc.<\/strong>\n <\/p>\n

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant\u2019s lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of \u03b1v<\/sub>\u00df8<\/sub>\u00a0and \u03b1v<\/sub>\u00df1<\/sub>\u00a0integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant\u2019s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells.<\/p>\n

For additional information on Pliant, visit\u00a0www.PliantRx.com<\/a> and follow us on\u00a0X<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0Facebook<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include express or implied statements regarding ongoing clinical trial development of PLN-101095, including timing of enrollment and data; the potential benefits of PLN-101095; receipt of Fast Track designation and implications thereof; and Pliant\u2019s plans for the continued development of PLN-101095 among others, including its integrin-based drug delivery platform. Because such statements deal with future events and are based on Pliant\u2019s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of Pliant\u2019s product candidates, including any delays in Pliant\u2019s ongoing or planned preclinical or clinical trials; the risks inherent in the drug development process, including obtaining regulatory approval, even with Fast Track Designation; the impact of current macroeconomic, geopolitical and marketplace conditions on Pliant\u2019s business, operations, clinical supply and plans; Pliant\u2019s reliance on single-source third parties located in foreign jurisdictions, including China, for critical aspects of Pliant development operations; risks regarding the accuracy of Pliant\u2019s estimates of expenses and timing of development, its capital requirements and the sufficiency of its cash to support planned operations; and Pliant\u2019s ability to obtain and maintain intellectual property protection for Pliant\u2019s product candidates; among others. These and additional risks are discussed in the sections titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” in Pliant\u2019s Quarterly Report on Form 10-Q for the period ended June 30, 2026, as filed with the Securities and Exchange Commission (SEC) and available on the SEC’s website, as may be amended or supplemented with future SEC filings. Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.<\/p>\n

\n Investor and Media Contact:<\/strong>
\n
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PLN-101095 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Poster Presentations Title: Selective targeting of integrins \u03b1v\u03b28 and \u03b1v\u03b21 improves anti-tumor responses mediated by immune checkpoint inhibition Nika Rajabian, Ph.D., Postdoctoral Fellow from the National Cancer Institute, presented data demonstrating that blocking of integrins \u03b1v\u03b28 and \u03b1v\u03b21 in combination with anti-PD-1 reduced TGF-\u03b2 signaling leading to modulation of fibroblastic cell populations in the tumor microenvironment and increased infiltration and activation of cytotoxic CD8+ T cells. This resulted in improved anti-tumor activity and survival. Researchers concluded … <\/p>\n

Continue reading “Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018794","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PLN-101095 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Poster Presentations Title: Selective targeting of integrins \u03b1v\u03b28 and \u03b1v\u03b21 improves anti-tumor responses mediated by immune checkpoint inhibition Nika Rajabian, Ph.D., Postdoctoral Fellow from the National Cancer Institute, presented data demonstrating that blocking of integrins \u03b1v\u03b28 and \u03b1v\u03b21 in combination with anti-PD-1 reduced TGF-\u03b2 signaling leading to modulation of fibroblastic cell populations in the tumor microenvironment and increased infiltration and activation of cytotoxic CD8+ T cells. This resulted in improved anti-tumor activity and survival. Researchers concluded … Continue reading "Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T15:05:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer\",\"datePublished\":\"2026-11-09T15:05:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\"},\"wordCount\":950,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\",\"name\":\"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=\",\"datePublished\":\"2026-11-09T15:05:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PLN-101095 at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Poster Presentations Title: Selective targeting of integrins \u03b1v\u03b28 and \u03b1v\u03b21 improves anti-tumor responses mediated by immune checkpoint inhibition Nika Rajabian, Ph.D., Postdoctoral Fellow from the National Cancer Institute, presented data demonstrating that blocking of integrins \u03b1v\u03b28 and \u03b1v\u03b21 in combination with anti-PD-1 reduced TGF-\u03b2 signaling leading to modulation of fibroblastic cell populations in the tumor microenvironment and increased infiltration and activation of cytotoxic CD8+ T cells. This resulted in improved anti-tumor activity and survival. Researchers concluded … Continue reading \"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-09T15:05:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer","datePublished":"2026-11-09T15:05:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/"},"wordCount":950,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","name":"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=","datePublished":"2026-11-09T15:05:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjkxOSM3OTUzMDE5IzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentation-of-pln-101095-preclinical-and-clinical-data-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018794"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018794\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}